Corporate Overview

Corporate Overview

Products

Products

Our team


Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum.

Read more

Products


Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum.

Read more

Business Development


Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum.

Read more

Juno is led by a team of highly skilled experts, with decades of collective industry experience to drawn on, they offer a breadth of pharmaceutical knowledge. This knowledge paired with a genuine passion for innovation and to drive value consistently delivers superior outcomes for suppliers, customers and shareholders alike.

Contura


United Kingdom

UK-headquartered pan-European niche medical device and pharmaceutical company, with a focus on urology products
See website

Contura


United Kingdom

UK-headquartered pan-European niche medical device and pharmaceutical company, with a focus on urology products
See website

Contura


United Kingdom

UK-headquartered pan-European niche medical device and pharmaceutical company, with a focus on urology products
See website

Contura


United Kingdom

UK-headquartered pan-European niche medical device and pharmaceutical company, with a focus on urology products
See website

Contura


United Kingdom

UK-headquartered pan-European niche medical device and pharmaceutical company, with a focus on urology products
See website
Standard Generics

Small molecule generics delivered in standard presentations.
Value Added Generics

Research-focused approach to deliver improved formulation, new presentations & improved user experience.
Value Added Generics

Research-focused approach to deliver improved formulation, new presentations & improved user experience.
Value Added Generics

Research-focused approach to deliver improved formulation, new presentations & improved user experience.
Value Added Generics

Research-focused approach to deliver improved formulation, new presentations & improved user experience.
Ian Jacobson
Chief Executive Officer

Ian has over 35 years of pharmaceutical industry experience. Prior to founding Juno, Ian worked for Arrow Pharmaceuticals as the CEO of Cobalt Pharmaceuticals from 2000 – 2010, he was also instrumental in the development of Arrow’s other international business units. As CEO of Cobalt, Ian was responsible for managing over $300 million in annual sales and played a key role in facilitating the sale of Arrow to Watson Pharmaceuticals (now Actavis) in June 2009 for over $2.4 billion USD. Prior to his work at Arrow, Ian was an executive at Par Pharmaceuticals (US) in the Office of the President, Gingham Canada as Executive Vice President and Amerpharm/Merck KGaA as a Senior Executive in the international generics business.

Read more

Ian Jacobson
Chief Executive Officer

Ian has over 35 years of pharmaceutical industry experience. Prior to founding Juno, Ian worked for Arrow Pharmaceuticals as the CEO of Cobalt Pharmaceuticals from 2000 – 2010, he was also instrumental in the development of Arrow’s other international business units. As CEO of Cobalt, Ian was responsible for managing over $300 million in annual sales and played a key role in facilitating the sale of Arrow to Watson Pharmaceuticals (now Actavis) in June 2009 for over $2.4 billion USD. Prior to his work at Arrow, Ian was an executive at Par Pharmaceuticals (US) in the Office of the President, Gingham Canada as Executive Vice President and Amerpharm/Merck KGaA as a Senior Executive in the international generics business.

Read more

Ian Jacobson
Chief Executive Officer

Ian has over 35 years of pharmaceutical industry experience. Prior to founding Juno, Ian worked for Arrow Pharmaceuticals as the CEO of Cobalt Pharmaceuticals from 2000 – 2010, he was also instrumental in the development of Arrow’s other international business units. As CEO of Cobalt, Ian was responsible for managing over $300 million in annual sales and played a key role in facilitating the sale of Arrow to Watson Pharmaceuticals (now Actavis) in June 2009 for over $2.4 billion USD. Prior to his work at Arrow, Ian was an executive at Par Pharmaceuticals (US) in the Office of the President, Gingham Canada as Executive Vice President and Amerpharm/Merck KGaA as a Senior Executive in the international generics business.

Read more

Ian Jacobson
Chief Executive Officer

Ian has over 35 years of pharmaceutical industry experience. Prior to founding Juno, Ian worked for Arrow Pharmaceuticals as the CEO of Cobalt Pharmaceuticals from 2000 – 2010, he was also instrumental in the development of Arrow’s other international business units. As CEO of Cobalt, Ian was responsible for managing over $300 million in annual sales and played a key role in facilitating the sale of Arrow to Watson Pharmaceuticals (now Actavis) in June 2009 for over $2.4 billion USD. Prior to his work at Arrow, Ian was an executive at Par Pharmaceuticals (US) in the Office of the President, Gingham Canada as Executive Vice President and Amerpharm/Merck KGaA as a Senior Executive in the international generics business.

Read more

Ian Jacobson
Chief Executive Officer

Ian has over 35 years of pharmaceutical industry experience. Prior to founding Juno, Ian worked for Arrow Pharmaceuticals as the CEO of Cobalt Pharmaceuticals from 2000 – 2010, he was also instrumental in the development of Arrow’s other international business units. As CEO of Cobalt, Ian was responsible for managing over $300 million in annual sales and played a key role in facilitating the sale of Arrow to Watson Pharmaceuticals (now Actavis) in June 2009 for over $2.4 billion USD. Prior to his work at Arrow, Ian was an executive at Par Pharmaceuticals (US) in the Office of the President, Gingham Canada as Executive Vice President and Amerpharm/Merck KGaA as a Senior Executive in the international generics business.

Read more

WHY PARTNER WITH JUNO

We are Juno, a global specialist company in the pharmaceuticals market. We are a team of innovative entrepreneurs, with years of collective healthcare industry experience and widespread international networks. Spanning across four continents, we offer an extensive product portfolio with a focus on niche and differentiated products.

We’re passionate about building bridges to unmet medical needs and supporting our customers and patient groups with access to pharmaceuticals. We constantly strive to find differentiated ways of engaging customers and identifying new opportunities. We are creative and committed partners with a focus on delivering value across the full spectrum of our industry.

Product 1
Product 1
Product 1
Product 1

Send us an email


Have a question about our products, partnering with us, career opportunities or would like to share any feedback or ideas with us?

Please use the form field below

 

Head Office


Juno Pharmaceuticals Inc.
555 Richmond Street West,
Suite 1004, Toronto,
Ontario M5V 3B1, Canada

+1 905 881 4410 Ext 203

Email: Jesse Buckstein

Business Development


Juno Pharmaceuticals Inc.
1st Floor, The Coach House,
Cross Heyes,
Malmesbury SN16 9BE

+44 (0) 1666 848 450

Email: UK Office

Acquisitions


AUSTRALIA - Juno Acquires Amneal Hospital Product Portfolio

Read more

Major Launches


AUSTRALIA - Juno Pharmaceuticals Acquires Noradrenaline 2 mg/2 mL & 4 mg/4 mL from Mayne Pharma

Read more

News


EUROPE - Speciality European Pharma Limited to rebrand as Contura in order to consolidate its corporate structure and drive growth

Read more

AUSTRALIA – Celltrion Healthcare and Juno Pharmaceuticals Partnership

Celltrion Healthcare Australia (Celltrion) and Juno Pharmaceuticals (Juno) have entered in to a co-marketing partnership, covering the biosimilar products Herzuma (biosimilar trastuzumab), and Truxima (biosimilar rituximab).

AUSTRALIA – Juno Pharmaceuticals Acquires Noradrenaline 2 mg/2 mL & 4 mg/4 mL from Mayne Pharma

Juno Pharmaceuticals is pleased to announce the acquisition of noradrenaline 2 mg/2 mL and 4 mg/4 mL concentrated injection from Mayne Pharma; an important addition to Juno’s growing range of vasopressors and critical care medicines.

AUSTRALIA – Juno Acquires Local Portfolio of Essential Injectable Medicines from AstraZeneca

Juno Pharmaceuticals Pty Ltd is pleased to announce the acquisition of a local portfolio of essential injectable medicines from AstraZeneca Pty Ltd.

Our Location

The Juno team is always actively seeking new partnership opportunities. If you are interested in learning more about us, please contact our Corporate Development Director, Jesse: jessebuckstein@www.junopharm.com